top of page

ENHERTU - Discover a new indication & how it may help certain patients with unmet needs ~ March 4th


ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

PP-US-ENG-0309_DSI Enhertu Live Broadcas
Download • 383KB

25 views0 comments


bottom of page